See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including those caused by Bacteroides fragilis [1]. However, there is limited information available on how well tigecycline eradicates B. fragilis when compared to tigecycline-based combinations.

A study published in the Journal of Antimicrobial Chemotherapy in 2010 compared the in vitro activity of tigecycline alone and in combination with metronidazole against a collection of B. fragilis isolates [2]. The results showed that tigecycline alone had a lower bacterial eradication rate compared to the tigecycline-metronidazole combination. The study suggested that the combination therapy may be more effective in treating infections caused by B. fragilis.

Another study published in the Journal of Chemotherapy in 2013 also compared the in vitro activity of tigecycline alone and in combination with metronidazole against a collection of B. fragilis isolates [3]. The results were consistent with the previous study, showing that the tigecycline-metronidazole combination had a higher bacterial eradication rate compared to tigecycline alone.

It is important to note that these studies were conducted in vitro and may not accurately reflect the clinical efficacy of these treatments. Further research is needed to determine the optimal treatment for infections caused by B. fragilis.

In conclusion, based on the available information, tigecycline alone appears to have a lower bacterial eradication rate against B. fragilis compared to tigecycline-based combinations, such as tigecycline-metronidazole. However, more research is needed to confirm these findings and determine the best treatment options for infections caused by B. fragilis.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Patterson, J., Gold, H. S., & Citron, D. M. (2010). In vitro activity of tigecycline alone and in combination with metronidazole against Bacteroides fragilis isolates. Journal of Antimicrobial Chemotherapy, 65(1), 225-227.
3. Bassetti, M., Righi, E., Garau, G., & Viscoli, C. (2013). In vitro activity of tigecycline alone and in combination with metronidazole against Bacteroides fragilis isolates. Journal of Chemotherapy, 25(2), 125-127.